Comprehensive approach to diabetic nephropathy

Kidney Research and Clinical Practice

Volumn 33, Issue 3, 2014, Pages 121-131

  Satirapoj, Bancha ^a   Adler, Sharon G ^b  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Glomerular hyperfiltration; Microalbuminuria

Indexed keywords

ACARBOSE; ALISKIREN; ALOGLIPTIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; IRBESARTAN; LINAGLIPTIN; LOSARTAN; METFORMIN; NATEGLINIDE; OLMESARTAN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL; VILDAGLIPTIN;

ALBUMINURIA; ARTERIOLE; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; END STAGE RENAL DISEASE; ENVIRONMENTAL FACTOR; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEREDITY; HUMAN; HYALINE DEGENERATION; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY INTERSTITIUM; MESANGIUM; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 84907879841     PISSN: 22119132     EISSN: 22119140     Source Type: Journal    
DOI: 10.1016/j.krcp.2014.08.001     Document Type: Review

References (101)

1. AJ Collins, RN Foley, B Chavers, D Gilbertson, C Herzog, K Johansen, B Kasiske, N Kutner, J Liu St, W Peter, H Guo, S Gustafson, B Heubner, K Lamb, S Li, Y Peng, Y Qiu, T Roberts, M Skeans, J Snyder, C Solid, B Thompson, C Wang, E Weinhandl, D Zaun, C Arko, SC Chen, F Daniels, J Ebben, E Frazier, C Hanzlik, R Johnson, D Sheets, X Wang, B Forrest, E Constantini, S Everson, P Eggers, and L Agodoa United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States Am J Kidney Dis 59 2012 e1 e420
2. M Afkarian, MC Sachs, B Kestenbaum, IB Hirsch, KR Tuttle, J Himmelfarb, and IH de Boer Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 2013 302 308
3. R Trevisan, and G Viberti Genetic factors in the development of diabetic nephropathy J Lab Clin Med 126 1995 342 349
4. S Adler, M Pahl, H Abboud, S Nicholas, E Ipp, and M Seldin Mexican-American admixture mapping analyses for diabetic nephropathy in type 2 diabetes mellitus Semin Nephrol 30 2010 141 149
5. BI Freedman, M Bostrom, P Daeihagh, and DW Bowden Genetic factors in diabetic nephropathy Clin J Am Soc Nephrol 2 2007 1306 1316
6. B Satirapoj, O Supasyndh, R Dispan, D Punpanich, S Tribanyatkul, and P Choovichian Apolipoprotein E genetic polymorphisms and the development of nephropathy in type 2 diabetes J Med Assoc Thai 96 2013 1119 1126
7. JR Schelling, HE Abboud, SB Nicholas, MV Pahl, JR Sedor, SG Adler, NH Arar, DW Bowden, RC Elston, BI Freedman, KA Goddard, X Guo, RL Hanson, E Ipp, SK Iyengar, G Jun, WH Kao, BS Kasinath, PL Kimmel, MJ Klag, WC Knowler, RG Nelson, RS Parekh, SR Quade, SS Rich, MF Saad, M Scavini, MW Smith, K Taylor, CA Winkler, PG Zager, and VO Shah Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND) Diabetes 57 2008 235 243
8. CW McDonough, PJ Hicks, L Lu, CD Langefeld, BI Freedman, and DW Bowden The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans Hum Genet 126 2009 265 275
9. Z Lin, G Huang, J Zhang, and X Lin Adiponectin gene polymorphisms and susceptibility to diabetic nephropathy: a meta-analysis Ren Fail 36 2014 478 487
10. MG Pezzolesi, P Katavetin, M Kure, GD Poznik, J Skupien, JC Mychaleckyj, SS Rich, JH Warram, and AS Krolewski Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy Diabetes 58 2009 2698 2702
11. JH Kim, HD Shin, BL Park, MK Moon, YM Cho, YH Hwang, KW Oh, SY Kim, HK Lee, C Ahn, and KS Park SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy Diabetes 55 2006 843 848
12. A Shimazaki, Y Kawamura, A Kanazawa, A Sekine, S Saito, T Tsunoda, D Koya, T Babazono, Y Tanaka, M Matsuda, K Kawai, T Iizumi, M Imanishi, T Shinosaki, T Yanagimoto, M Ikeda, S Omachi, A Kashiwagi, K Kaku, Y Iwamoto, R Kawamori, R Kikkawa, M Nakajima, Y Nakamura, and S Maeda Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy Diabetes 54 2005 1171 1178
13. S Martini, V Nair, SR Patel, F Eichinger, RG Nelson, EJ Weil, MG Pezzolesi, AS Krolewski, A Randolph, BJ Keller, T Werner, and M Kretzler From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy Diabetes 62 2013 2605 2612
14. CW McDonough, ND Palmer, PJ Hicks, BH Roh, SS An, JN Cooke, JM Hester, MR Wing, MA Bostrom, ME Rudock, JP Lewis, ME Talbert, RA Blevins, L Lu, MC Ng, MM Sale, J Divers, CD Langefeld, BI Freedman, and DW Bowden A genome-wide association study for diabetic nephropathy genes in African Americans Kidney Int 79 2011 563 572
15. S Shantikumar, A Caporali, and C Emanueli Role of microRNAs in diabetes and its cardiovascular complications Cardiovasc Res 93 2012 583 593
16. BA Perkins, LH Ficociello, KH Silva, DM Finkelstein, JH Warram, and AS Krolewski Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 2003 2285 2293
17. HH Parving Renoprotection in diabetes: genetic and non-genetic risk factors and treatment Diabetologia 41 1998 745 759
18. Rossing P: Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49:11-19, 2006
19. PE Pergola, P Raskin, RD Toto, CJ Meyer, JW Huff, EB Grossman, M Krauth, S Ruiz, P Audhya, H Christ-Schmidt, J Wittes, and DG Warnock Investigators BS: Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
20. B Satirapoj Review on pathophysiology and treatment of diabetic kidney disease J Med Assoc Thai 93 2010 S228 S241
21. B Satirapoj Nephropathy in diabetes Adv Exp Med Biol 771 2012 107 122
22. FN Ziyadeh, and G Wolf Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy Curr Diabetes Rev 4 2008 39 45
23. CW Heilig, DK Deb, A Abdul, H Riaz, LR James, J Salameh, and NS Nahman Jr GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy Am J Nephrol 38 2013 39 49
24. T Dai, R Natarajan, CC Nast, J LaPage, P Chuang, J Sim, L Tong, M Chamberlin, S Wang, and SG Adler Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton Kidney Int 69 2006 806 814
25. AK Singh, W Mo, G Dunea, and JA Arruda Effect of glycated proteins on the matrix of glomerular epithelial cells J Am Soc Nephrol 9 1998 802 810
26. H Ha, IA Hwang, JH Park, and HB Lee Role of reactive oxygen species in the pathogenesis of diabetic nephropathy Diabetes Res Clin Pract 1 2008 S42 S45
27. LL Dugan, YH You, SS Ali, M Diamond-Stanic, S Miyamoto, AE DeCleves, A Andreyev, T Quach, S Ly, G Shekhtman, W Nguyen, A Chepetan, TP Le, L Wang, M Xu, KP Paik, A Fogo, B Viollet, A Murphy, F Brosius, RK Naviaux, and K Sharma AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function J Clin Invest 123 2013 4888 4899
28. JF Navarro-Gonzalez, and C Mora-Fernandez The role of inflammatory cytokines in diabetic nephropathy J Am Soc Nephrol 19 2008 433 442
29. CG Ihm, GS Lee, CC Nast, A Artishevsky, R Guillermo, PS Levin, RJ Glassock, and SG Adler Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes Kidney Int 41 1992 768 777
30. M Kato, NE Castro, and R Natarajan MicroRNAs: potential mediators and biomarkers of diabetic complications Free Radic Biol Med 64 2013 85 94
31. P Kantharidis, B Wang, RM Carew, and HY Lan Diabetes complications: the microRNA perspective Diabetes 60 2011 1832 1837
32. J Long, Y Wang, W Wang, BH Chang, and FR Danesh MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy J Biol Chem 286 2011 11837 11848
33. BN Chau, C Xin, J Hartner, S Ren, AP Castano, G Linn, J Li, PT Tran, V Kaimal, X Huang, AN Chang, S Li, A Kalra, M Grafals, D Portilla, DA MacKenna, SH Orkin, and JS Duffield MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways Sci Transl Med 4 2012 121ra18
34. National Kidney F KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update Am J Kidney Dis 60 2012 850 886
35. P Chuankrekkul, B Satirapoj, C Jumroendararasamee, and S Vongkulsiri Correlation between clinical diabetic nephropathy and severity of diabetic retinopathy in type 2 diabetic patients J Nephrol Soc Thai 19 2013 41 46
36. TW Tervaert, AL Mooyaart, K Amann, AH Cohen, HT Cook, CB Drachenberg, F Ferrario, AB Fogo, M Haas, E de Heer, K Joh, LH Noel, J Radhakrishnan, SV Seshan, IM Bajema, and JA Bruijn Pathologic classification of diabetic nephropathy J Am Soc Nephrol 21 2010 556 563
37. SG Adler, SW Kang, S Feld, DR Cha, L Barba, L Striker, G Striker, BL Riser, J LaPage, and CC Nast Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40 2002 184 188
38. EN Ellis, MW Steffes, FC Goetz, DE Sutherland, and SM Mauer Glomerular filtration surface in type I diabetes mellitus Kidney Int 29 1986 889 894
39. P Fioretto, MW Steffes, DE Sutherland, and M Mauer Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression Kidney Int 48 1995 1929 1935
40. S Adler, LJ Striker, GE Striker, DT Perkinson, J Hibbert, and WG Couser Studies of progressive glomerular sclerosis in the rat Am J Pathol 123 1986 553 562
41. B Satirapoj, CC Nast, and SG Adler Novel insights into the relationship between glomerular pathology and progressive kidney disease Adv Chronic Kidney Dis 19 2012 93 100
42. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus Diabetes Control and Complications Trial J Pediatr 125 1994 177 188
43. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
44. S Kawazu, S Tomono, M Shimizu, N Kato, T Ohno, C Ishii, K Murata, T Watanabe, K Negishi, M Suzuki, M Takahashi, and J Ishii The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study J Diabetes Complications 8 1994 13 17
45. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
46. H Mulec, G Blohme, B Grande, and S Bjorck The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy Nephrol Dial Transplant 13 1998 651 655
47. DER Group, IH de Boer, W Sun, PA Cleary, JM Lachin, ME Molitch, MW Steffes, and B Zinman Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 2011 2366 2376
48. P Fioretto, MW Steffes, DE Sutherland, FC Goetz, and M Mauer Reversal of lesions of diabetic nephropathy after pancreas transplantation N Engl J Med 339 1998 69 75
49. P Fioretto, DE Sutherland, B Najafian, and M Mauer Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients Kidney Int 69 2006 907 912
50. M Shichiri, H Kishikawa, Y Ohkubo, and N Wake Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care 23 2000 B21 B29
51. RR Holman, SK Paul, MA Bethel, DR Matthews, and HA Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
52. Action to Control Cardiovascular Risk in Diabetes Study Group: HC Gerstein, ME Miller, RP Byington, DC Goff, JT Bigger, JB Buse, WC Cushman, S Genuth, F Ismail-Beigi, RH Grimm Jr, JL Probstfield, DG Simons-Morton, and WT Friedewald Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
53. A Patel, S MacMahon, J Chalmers, B Neal, L Billot, M Woodward, M Marre, M Cooper, P Glasziou, D Grobbee, P Hamet, S Harrap, S Heller, L Liu, G Mancia, CE Mogensen, C Pan, N Poulter, A Rodgers, B Williams, S Bompoint, BE de Galan, R Joshi, and F Travert Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
54. W Duckworth, C Abraira, T Moritz, D Reda, N Emanuele, PD Reaven, FJ Zieve, J Marks, SN Davis, R Hayward, SR Warren, S Goldman, M McCarren, ME Vitek, WG Henderson, and GD Huang Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
55. SG Coca, F Ismail-Beigi, N Haq, HM Krumholz, and CR Parikh Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes Arch Intern Med 172 2012 761 769
56. R Arem Hypoglycemia associated with renal failure Endocrinol Metab Clin North Am 18 1989 103 121
57. N Cano Bench-to-bedside review: glucose production from the kidney Crit Care 6 2002 317 321
58. B Satirapoj, O Supasyndh, P Phantana-Angkul, P Ruangkanchanasetr, N Nata, A Chaiprasert, I Kanjanakul, and P Choovichian Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes J Med Assoc Thai 94 2011 S87 S93
59. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S12-S154, 2007
60. KM Andrassy Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease' Kidney Int 84 2013 622 623
61. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 1 2014 S14 S80
62. M Inaba, S Okuno, Y Kumeda, S Yamada, Y Imanishi, T Tabata, M Okamura, S Okada, T Yamakawa, E Ishimura, and Y Nishizawa Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection J Am Soc Nephrol 18 2007 896 903
63. BI Freedman, L Andries, ZK Shihabi, MV Rocco, JR Byers, CY Cardona, MA Pickard, DL Henderson, MV Sadler, LM Courchene, JR Jordan, SS Balderston, AD Graham, VL Mauck, GB Russell, and AJ Bleyer Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients Clin J Am Soc Nephrol 6 2011 1635 1643
64. HS Chen, TE Wu, HD Lin, TS Jap, LC Hsiao, SH Lee, and SH Lin Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4 Am J Kidney Dis 55 2010 867 874
65. AS Group, WC Cushman, GW Evans, RP Byington, DC Goff Jr, RH Grimm Jr, JA Cutler, DG Simons-Morton, JN Basile, MA Corson, JL Probstfield, L Katz, KA Peterson, WT Friedewald, JB Buse, JT Bigger, HC Gerstein, and F Ismail-Beigi Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
66. MA Pohl, S Blumenthal, DJ Cordonnier, F De Alvaro, G Deferrari, G Eisner, E Esmatjes, RE Gilbert, LG Hunsicker, JB de Faria, R Mangili, J Moore Jr, E Reisin, E Ritz, G Schernthaner, S Spitalewitz, H Tindall, RA Rodby, and EJ Lewis Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations J Am Soc Nephrol 16 2005 3027 3037
67. MA Roberts Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease Nephrology (Carlton) 19 2014 53 55
68. R Zatz, BR Dunn, TW Meyer, S Anderson, HG Rennke, and BM Brenner Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension J Clin Invest 77 1986 1925 1930
69. AV Chobanian, GL Bakris, HR Black, WC Cushman, LA Green, JL Izzo Jr, DW Jones, BJ Materson, S Oparil, JT Wright Jr, and EJ Roccella The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
70. G Viberti, CE Mogensen, LC Groop, and JF Pauls Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA 271 1994 275 279
71. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39:587-593, 1996
72. EJ Lewis, LG Hunsicker, RP Bain, and RD Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1993 1456 1462
73. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134 2001 370 379
74. P Ruggenenti, A Fassi, AP Ilieva, S Bruno, IP Iliev, V Brusegan, N Rubis, G Gherardi, F Arnoldi, M Ganeva, B Ene-Iordache, F Gaspari, A Perna, A Bossi, R Trevisan, AR Dodesini, and G Remuzzi Bergamo Nephrologic Diabetes Complications Trial I: Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951
75. R Bilous, N Chaturvedi, AK Sjolie, J Fuller, R Klein, T Orchard, M Porta, and HH Parving Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 2009 11 20
76. M Mauer, B Zinman, R Gardiner, S Suissa, A Sinaiko, T Strand, K Drummond, S Donnelly, P Goodyer, MC Gubler, and R Klein Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 2009 40 51
77. H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, A Mimran, TJ Rabelink, E Ritz, LM Ruilope, LC Rump, and G Viberti Investigators RT: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 2011 907 917
78. HH Parving, H Lehnert, J Brochner-Mortensen, R Gomis, S Andersen, and P Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
79. G Viberti, and NM Wheeldon Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 2002 672 678
80. EJ Lewis, LG Hunsicker, WR Clarke, T Berl, MA Pohl, JB Lewis, E Ritz, RC Atkins, R Rohde, and I Raz Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
81. BM Brenner, ME Cooper, D de Zeeuw, WF Keane, WE Mitch, HH Parving, G Remuzzi, SM Snapinn, Z Zhang, and S Shahinfar Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
82. AH Barnett, SC Bain, P Bouter, B Karlberg, S Madsbad, J Jervell, and J Mustonen Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy N Engl J Med 351 2004 1952 1961
83. R Kunz, C Friedrich, M Wolbers, and JF Mann Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 2008 30 48
84. JF Mann, RE Schmieder, M McQueen, L Dyal, H Schumacher, J Pogue, X Wang, A Maggioni, A Budaj, S Chaithiraphan, K Dickstein, M Keltai, K Metsarinne, A Oto, A Parkhomenko, LS Piegas, TL Svendsen, KK Teo, and S Yusuf Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
85. LF Fried, N Emanuele, JH Zhang, M Brophy, TA Conner, W Duckworth, DJ Leehey, PA McCullough, T OConnor, PM Palevsky, RF Reilly, SL Seliger, SR Warren, S Watnick, P Peduzzi, and P Guarino Investigators VN-D: Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
86. G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm, T. Christiaens, R. Cifkova, G.D. Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, and F. Zannad ESH/ESC Guidelines for the management of arterial hypertension Blood Press 22 2013 193 278
87. HH Parving, F Persson, JB Lewis, EJ Lewis, and NK Hollenberg Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2008 2433 2446
88. HH Parving, BM Brenner, JJ McMurray, D de Zeeuw, SM Haffner, SD Solomon, N Chaturvedi, F Persson, AS Desai, M Nicolaides, A Richard, Z Xiang, P Brunel, and MA Pfeffer Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
89. K Rossing, KJ Schjoedt, BR Jensen, F Boomsma, and HH Parving Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 2005 1190 1198
90. AK Ahmed, NS Kamath, M El Kossi, and AM El Nahas The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease Nephrol Dial Transplant 25 2010 3977 3982
91. AS Go, GM Chertow, D Fan, CE McCulloch, and CY Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
92. D de Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, A Goldsberry, M Houser, M Krauth, HJ Lambers Heerspink, JJ McMurray, CJ Meyer, HH Parving, G Remuzzi, RD Toto, ND Vaziri, C Wanner, J Wittes, D Wrolstad, and GM Chertow Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 2013 2492 2503
93. WK Bolton, DC Cattran, ME Williams, SG Adler, GB Appel, K Cartwright, PG Foiles, BI Freedman, P Raskin, RE Ratner, BS Spinowitz, FC Whittier, and JP Wuerth Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am J Nephrol 24 2004 32 40
94. SG Adler, S Schwartz, ME Williams, C Arauz-Pacheco, WK Bolton, T Lee, D Li, TB Neff, PR Urquilla, and KL Sewell Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria Clin J Am Soc Nephrol 5 2010 1420 1428
95. KR Tuttle, GL Bakris, RD Toto, JB McGill, K Hu, and PW Anderson The effect of ruboxistaurin on nephropathy in type 2 diabetes Diabetes Care 28 2005 2686 2690
96. DK Packham, R Wolfe, AT Reutens, T Berl, HL Heerspink, R Rohde, S Ivory, J Lewis, I Raz, TB Wiegmann, JC Chan, D de Zeeuw, EJ Lewis, and RC Atkins Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy J Am Soc Nephrol 23 2012 123 130
97. HL Heerspink, T Greene, JB Lewis, I Raz, RD Rohde, LG Hunsicker, SL Schwartz, S Aronoff, MA Katz, GM Eisner, JH Mersey, and TB Wiegmann Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria Nephrol Dial Transplant 23 2008 1946 1954
98. K Sharma, JH Ix, AV Mathew, M Cho, A Pflueger, SR Dunn, B Francos, S Sharma, B Falkner, TA McGowan, M Donohue, S Ramachandrarao, R Xu, FC Fervenza, and JB Kopp Pirfenidone for diabetic nephropathy J Am Soc Nephrol 22 2011 1144 1151
99. CW Park, HW Kim, SH Ko, JH Lim, GR Ryu, HW Chung, SW Han, SJ Shin, BK Bang, MD Breyer, and YS Chang Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice J Am Soc Nephrol 18 2007 1227 1238
100. WJ Liu, SH Xie, YN Liu, W Kim, HY Jin, SK Park, YM Shao, and TS Park Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats J Pharmacol Exp Ther 340 2012 248 255
101. SY Goh, M Jasik, and ME Cooper Agents in development for the treatment of diabetic nephropathy Expert Opin Emerg Drugs 13 2008 447 463